Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Azad

Showing results (261-270 of 353) with videos related to

Pageof 36
Sort By:
The American Journal of Pathology|November 9, 2013
Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genesSoma Ghosh, Surojit Sur, Sashidhar R Yerram, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
The Prostate|July 13, 2021
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
AIDS Research and Human Retroviruses|March 20, 1997
Simian T cell leukemia virus type I from naturally infected feral monkeys from central and west Africa encodes a 91-amino acid p12 (ORF-I) protein as opposed to a 99-amino acid protein encoded by HTLV type I from humansN K Saksena, A Srinivasan, Y C Ge, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
<sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancerAmy Davies, Marcus Foo, Chun Loo Gan, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
Small (Weinheim an Der Bergstrasse, Germany)|October 26, 2020
Exploring High Aspect Ratio Gold Nanotubes as Cytosolic Agents: Structural Engineering and Uptake into Mesothelioma CellsSunjie Ye, Arsalan A Azad, Joseph E Chambers, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
Pageof 36

Showing results (261-270 of 353) with videos related to

Sort By:
Pageof 36
The American Journal of Pathology|November 9, 2013
Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genesSoma Ghosh, Surojit Sur, Sashidhar R Yerram, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
The Prostate|July 13, 2021
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
AIDS Research and Human Retroviruses|March 20, 1997
Simian T cell leukemia virus type I from naturally infected feral monkeys from central and west Africa encodes a 91-amino acid p12 (ORF-I) protein as opposed to a 99-amino acid protein encoded by HTLV type I from humansN K Saksena, A Srinivasan, Y C Ge, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
<sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancerAmy Davies, Marcus Foo, Chun Loo Gan, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
Small (Weinheim an Der Bergstrasse, Germany)|October 26, 2020
Exploring High Aspect Ratio Gold Nanotubes as Cytosolic Agents: Structural Engineering and Uptake into Mesothelioma CellsSunjie Ye, Arsalan A Azad, Joseph E Chambers, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
Pageof 36